Phase 1 KRAS G12C Mutation Clinical Trials
6 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–6 of 6 trials
Recruiting
Phase 1Phase 2
Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments
Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung CancerAdvanced Solid Tumors Harboring the KRAS G12C Mutation
Novartis Pharmaceuticals40 enrolled7 locationsNCT07468071
Recruiting
Phase 1Phase 2
A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations
Metastatic Colorectal CancerKRAS G12C Mutations
M.D. Anderson Cancer Center31 enrolled2 locationsNCT06412198
Recruiting
Phase 1
A Phase I Study of BAY3498264 Given Together With Sotorasib in Participants Who Have Advanced Solid Cancers With Specific Genetic Changes Called KRASG12C Mutation
Advanced Solid Tumors Harboring KRAS G12C Mutation
Bayer104 enrolled10 locationsNCT06659341
Recruiting
Phase 1
A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies
Solid Tumor MalignanciesCRC (Colorectal Cancer)KRAS G12C Mutation+1 more
Kumquat Biosciences Inc.140 enrolled11 locationsNCT06720987
Recruiting
Phase 1Phase 2
A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
Colorectal, CancerPancreatic CancerMetastatic Solid Tumor+5 more
Frontier Medicines Corporation403 enrolled26 locationsNCT06244771
Recruiting
Phase 1
Ladarixin With Sotorasib in Advanced NSCLC
Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation
NYU Langone Health40 enrolled6 locationsNCT05815173